Mode
Text Size
Log in / Sign up
Phase 4 N=219 Randomized Single-blind Treatment

Switching Medication to Treat Schizophrenia

Schizophrenia

Enrolled (actual)
219
Serious AEs
0.9%
Results posted
Dec 2013
Primary outcome: Primary: Number Who Discontinued Medication Within First 6 Study Months — 11; 23 participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Risperidone (Drug); Olanzapine (Drug); Ziprasidone (Drug); Quetiapine (Drug); Aripiprazole (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Icahn School of Medicine at Mount Sinai
Primary completion
Mar 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Number Who Discontinued Medication Within First 6 Study Months
11; 23
SECONDARY
Number of Participants Hospitalized
8; 9

Summary

This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.

Eligibility Criteria

Inclusion criteria

  • SCID diagnosis of schizophrenia or schizoaffective disorder
  • Partially remitted outpatients, defined as persons who have received clear symptomatic benefit from antipsychotic medication but remain symptomatic (due to lack of efficacy or inability to tolerate an efficacious dose) or suffer significant side effects
  • Treatment with antipsychotic medications for at least 2 months
  • Received at least 1 outpatient mental health service every 3 months for the past 6 months

Exclusion criteria

  • Severe symptoms or side effects that indicate the necessity for a medication change
  • Currently taking 3 or more antipsychotic medications for ongoing daily administration (PRN medications and mood stabilizers are allowable)
  • Treatment with clozapine
  • One or more nights spent in a psychiatric hospitalization within the past 3 months
  • Received services from a crisis intervention program within the past 3 months
  • Require placement in a skilled nursing facility as a result of a physical condition or disability
  • Criminal charges pending (once charges clear, the person will be considered)
  • Pregnant or breast feeding
  • Contraindication to any of the medications to which the patient might be assigned
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00044655). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search